Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
出版年份 2020 全文链接
标题
Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 122, Issue 10, Pages 1453-1460
出版商
Springer Science and Business Media LLC
发表日期
2020-03-16
DOI
10.1038/s41416-020-0786-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Pertuzumab in HER2-positive early breast cancer: current use and perspectives
- (2019) Daniel Eiger et al. Future Oncology
- Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) F Cardoso et al. ANNALS OF ONCOLOGY
- A pooled analysis of the cardiac events in the trastuzumab adjuvant trials
- (2019) Evandro de Azambuja et al. BREAST CANCER RESEARCH AND TREATMENT
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Abstract P5-21-08: Tolerability of the combination of lapatinib and trastuzumab in older patients with HER2 positive metastatic breast cancer
- (2018) T O'Connor et al. CANCER RESEARCH
- Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update
- (2018) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2018) Heikki Joensuu et al. JAMA Oncology
- 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- (2018) P Conte et al. ANNALS OF ONCOLOGY
- SAFE-HEaRt: A pilot study assessing the cardiac safety of HER2 targeted therapy in patients with HER2 positive breast cancer and reduced left ventricular function.
- (2018) Filipa Lynce et al. JOURNAL OF CLINICAL ONCOLOGY
- An individual patient level data pooled analysis of T-DM1 cardiac safety in HER2-positive (HER2+) metastatic breast cancer (MBC) patients.
- (2018) Noam Falbel Ponde et al. JOURNAL OF CLINICAL ONCOLOGY
- PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.
- (2018) Helena Margaret Earl et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction
- (2018) Somaira Nowsheen et al. Journal of the American Heart Association
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiac Safety of Dual Anti‐HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2‐Positive Breast Cancer
- (2017) Anthony F. Yu et al. ONCOLOGIST
- Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
- (2017) Roberta Florido et al. Journal of the American Heart Association
- Risk of Cardiovascular Disease from Cumulative Cigarette Use and the Impact of Smoking Intensity
- (2016) Jay H. Lubin et al. EPIDEMIOLOGY
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
- (2016) Jose Luis Zamorano et al. EUROPEAN HEART JOURNAL
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- (2016) Martine Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes
- (2016) Nishant Mohan et al. MOLECULAR CANCER THERAPEUTICS
- Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium
- (2016) Shanly C. Seferina et al. ONCOLOGIST
- Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
- (2015) D. Mavroudis et al. ANNALS OF ONCOLOGY
- Left ventricular ejection fraction estimation using mutual information on technetium-99m multiple-gated SPECT scans
- (2015) Shih-Neng Yang et al. Biomedical Engineering Online
- The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study
- (2015) Hart A. Goldhar et al. JNCI-Journal of the National Cancer Institute
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study
- (2015) Hart A. Goldhar et al. JNCI-Journal of the National Cancer Institute
- Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
- (2013) David Miles et al. BREAST CANCER RESEARCH AND TREATMENT
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
- (2011) Luigi Tarantini et al. JOURNAL OF CARDIAC FAILURE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
- (2008) Deepa Wadhwa et al. BREAST CANCER RESEARCH AND TREATMENT
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started